The Wegovy pill — Novo Nordisk's reformulated oral semaglutide for chronic weight management — launched into the same competitive frame as Lilly's small-molecule Foundayo (orforglipron). Coverage on this site has tracked the launch pricing, distribution channels, and head-to-head comparisons.
Key moves: Amazon Pharmacy expanded access to the oral Wegovy pill with both insurance and cash-pay options; NovoCare priced the 1.5mg starter dose at $149/month and moved the 4mg dose from $149 to $199 effective April 15, 2026; and indirect comparisons suggested oral Wegovy may produce greater weight loss than Foundayo (which leads on HbA1c). Novo's May 6 Q1 print confirmed the launch's strength: DKK 2.26B (~$354M) in Q1 sales — almost 2× the DKK 1.16B analyst consensus — on roughly 1.3 million Q1 prescriptions and 2 million-plus cumulative US scripts since the January 5 launch. Weekly retail volume was around 113,000 by early May, more than 20× Foundayo's Week 3 reading of 5,612.
Stories here cover the launch tracker, payer coverage, and head-to-head comparisons. See #oral-wegovy, #wegovy, and #foundayo.
Reuters reported May 5 that Novo Nordisk's Wegovy pill posted roughly 721,000 US prescriptions in Q1 per IQVIA, beating analyst expectations on volume but raising margin questions: about 450,000 of those scripts were for the cheapest 1.5 mg starter dose at $149/month. Lilly's Foundayo approval in early April closed Novo's window as the only oral obesity pill, and Wegovy injection prices have fallen rapidly amid intensifying competition. The Danish company's market value has shed more than $400 billion from its 2024 peak. Wednesday's Q1 print (May 6, 7:30 CEST) is the test: investors are watching whether Novo holds February's guidance of a 5–13% sales and operating-profit decline at constant exchange rates, and whether direct-to-consumer NovoCare and the WW Med+ + GoodRx channels can offset price pressure.
IQVIA data cited by Deutsche Bank analysts and Pharmaphorum showed Novo Nordisk's Wegovy pill at roughly 113,354 prescriptions in its most recent reported week, up from 105,366 the week prior. That puts Novo's January-launched oral semaglutide more than 20× ahead of Lilly's Foundayo Week 3 reading of 5,612, and the gap is from US retail-channel data alone — NovoCare Pharmacy direct-to-consumer volumes are additional. Lilly executives have asked analysts to wait 8–12 weeks for a clearer read, but the early Foundayo-versus-Wegovy-pill comparison continues to favor Novo on raw volume.
Two of the largest obesity drug makers report this week: Eli Lilly (April 30) with Foundayo (orforglipron) launch trajectory and Mounjaro/Zepbound dynamics under scrutiny — Lilly previously guided 2026 sales of $80-83 billion (25% growth); and Novo Nordisk (May 6) facing 5-13% guided sales decline as semaglutide loses exclusivity in China, Brazil, Canada, and as the Wegovy pill ramps. Goldman analysts model Lilly's oral GLP-1 capturing 60% of the daily-oral segment by 2030; Novo's projected at 21%. The Foundayo Week 1-2 prescription tracker has shown a slow start.
Eli Lilly shares fell April 24 after the latest weekly prescription data for Foundayo showed 3,707 scripts for the week ending April 17 — behind analyst expectations. For comparison, Novo's Wegovy pill reached 18,410 prescriptions in its second week after a January launch. RBC Capital Markets analyst Trung Huynh said early comparisons should be viewed cautiously but acknowledged the uptake is 'likely to be received negatively.' Fierce Pharma launched a weekly Oral GLP-1 Tracker to follow Foundayo and Wegovy pill head-to-head.
IQVIA tracking data reported April 21 showed Eli Lilly's newly-launched oral GLP-1 Foundayo (orforglipron) drew 1,390 prescriptions in its first full week (April 6-10), roughly 45% of the 3,071 Wegovy pill scripts in Novo Nordisk's launch week in January. Analyst consensus requires Foundayo to hit about 5.4 million prescriptions from April-December to generate $1.7 billion in 2026 revenue — a target that looks challenging at the current trajectory.